17 September 2018
News
17 September 2018
17 September 2018
Cambridge, UK, September 14 2018: Owlstone Medical Ltd (or the “Company”), a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
13 September 2018
Draft Coverage Supports the Use of InVisionFirst-Lung for Aiding in the Management of Patients with Advanced Non-Small-Cell Lung Cancer
12 September 2018
Babraham 10 September 2018: The Babraham Research Campus is delighted to announce Taylor Vinters and Silicon Valley Bank as the latest organisations to pledge support for the Babraham Research Campus’ life-science accelerator, Accelerate@Babraham.
The successfully defended patent protects novel compositions of a specific type and group of vaccines, called polysaccharide vaccines. Examples of polysaccharide vaccines are vaccines that are used to protect against Meningitis or Pneumonia. Such products are known to degrade over time, leading to gradual loss of potency.
$133 Million Deal Adds European Early Development Center of Excellence to Global Network
CAMBRIDGE, UK, 02 July 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis, announced today that it had been awarded substantial funding to support the development of a novel enzymatic approach to DNA synthesis. Innovate UK, the UK’s innovation agency, will co-fund the £1.3 million project, which will be undertaken in collaboration with Durham University.